EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Comparisons

Which eligibility and quality checks must come before commercial scoring?

Dose Diligence research deskSection 03 · Page 8 of 12Last updated 17 Nov 2026

Use a pass/hold gate. A cheap quote should not offset an unresolved product, licensing or quality issue.

GateEvidence to requestRecommended hold trigger
Identity and supply chainContracting entity, dispensing or manufacturing location, seller, shipper and product identifiersUnexplained entity mismatch or undisclosed fulfilment facility
Route eligibilityIntended use, relevant permissions and preparation-specific assessment where compounding is proposedReliance only on a licence, prescription, registration or historic shortage
Product and qualityProvenance, applicable inspection records, quality responses, storage instructions and recall proceduresUnresolved identity, sterility, potency, handling or investigation concerns
Destination readinessState-specific permissions and written product acceptanceA national marketing statement without facility-level evidence
Clinical responsibilityPrescribing, counselling, complaint and adverse-event responsibilitiesCommercial staff determining clinical changes or unclear escalation ownership
Information governanceData-flow map, role assessment, security evidence and appropriate agreementsUnknown data recipients, unclear permitted uses or unreviewed subcontractors

What do registration and inspection records actually establish?

Use public records as evidence inputs, not approval badges. FDA's outsourcing register contains registration and inspection-related information, and some fields are supplier-reported rather than FDA-verified. FDA also explains that a Form 483 records inspection observations and is not a final agency determination of a violation. Review the observation, response, subsequent action and current status together. (fda.gov)

For wholesalers, FDA says appropriate licensing and annual reporting are required for authorised-trading-partner status. Appearance in its reporting database does not itself establish FDA approval or compliance with all applicable requirements. (fda.gov)

How should a multi-state pharmacy coverage matrix work?

Use one row per dispensing facility, destination state and relevant activity—not one row per brand.

Suggested columns are legal entity, facility address, home-state licence, destination permission, sterile-compounding or outsourcing permission where relevant, restrictions, expiry, disciplinary review, exact product acceptance, operational capacity and evidence date.

California illustrates why the distinctions matter: a nonresident pharmacy shipping prescription medicines to its residents needs both a valid home-state licence and a California nonresident licence. Nonresident sterile compounding has an additional licensing requirement. These examples are not a substitute for reviewing every target state. (pharmacy.ca.gov)

How should clinics compare cold-chain and vial-wastage claims?

Require presentation-specific handling evidence and an executable exception process. FDA has reported concerns about compounded injectable GLP-1 products arriving warm or inadequately refrigerated. Its current advice also addresses contamination risk and discarding compounded multi-dose vials within 28 days of first use, even where a compounder's instructions allow longer. (fda.gov)

Ask the supplier to distinguish unopened shelf life, post-opening limits and shipping-excursion assessment. Do not model every labelled milligram as usable inventory, and do not apply a compounded-vial instruction indiscriminately to every approved presentation.

Is a business associate agreement always the answer?

No; determine the parties' actual roles and data uses. HHS distinguishes treatment disclosures to another healthcare provider from arrangements in which a business associate performs functions on a covered entity's behalf. Technology, analytics and other service relationships therefore require role-specific assessment rather than a blanket assumption that every pharmacy handoff has the same contracting requirement. (hhs.gov)

Explore the table row by row

A working view of the research

Identity and supply chain

Evidence to request
Contracting entity, dispensing or manufacturing location, seller, shipper and product identifiers
Recommended hold trigger
Unexplained entity mismatch or undisclosed fulfilment facility

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  2. fda.gov · Source 2 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/annual-licensure-reporting-wholesale-drug-distributors-and-third-party-logistics-providers
  3. pharmacy.ca.gov · Source 3 ↗https://www.pharmacy.ca.gov/applicants/phy.shtml
  4. fda.gov · Source 4 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  5. hhs.gov · Source 5 ↗https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
Section sources →